Skip to main content
OpenTrials

Clinical trial condition

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Explore clinical trials studying Metastatic Castration-resistant Prostate Cancer (mCRPC). Study availability and eligibility vary by location and protocol.

34 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC) trial results

Active, Not Recruiting

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NCT06334432

Conditions
Advanced Solid Tumor, Digestive System Diseases, Digestive System Neoplasms, +10 more
Locations
  • Karmanos Cancer Center Detroit, Michigan, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
  • Carolina BioOncology Institute Huntersville, North Carolina, United States
View Trial Details
Active, Not Recruiting

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

NCT04015622

Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Locations
  • BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre) Kelowna, British Columbia, Canada
  • BC Cancer - Centre for the North Prince George, British Columbia, Canada
  • BC Cancer - Surrey Centre Surrey, British Columbia, Canada
  • Sunnybrook Health Sciences Centre Toronto, British Columbia, Canada
View Trial Details
Active, Not Recruiting

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

NCT05032040

Conditions
Adenocarcinoma, Adenocarcinoma, Clear Cell, Adnexal Diseases, +34 more
Locations
  • Arizona Oncology Associates, PC - NAHOA Prescott, Arizona, United States
  • UCSD Moores Cancer Center La Jolla, California, United States
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • UCLA Medical Center Los Angeles, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804

Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Locations
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Urological Associates of Southern Arizona PC Tucson, Arizona, United States
  • Desert Hematology Oncology Medical Group Inc Rancho Mirage, California, United States
  • San Bernardino Urological Associates Medical Group San Bernardino, California, United States
View all 147 locations
View Trial Details

Related conditions